Fucheng Qiu1, Ping Gu1, Wencong Liu2, Dong Li3. 1. Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. 2. Department of Ultrasound, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. 3. Department of Vertigo Center, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Shijiazhuang, Hebei, China. lidong2018@vip.163.com.
Abstract
OBJECTIVE: This study aimed to explore the spectrum characteristics of Parkinson's disease (PD) patients with sleep disorders. METHODS: This retrospective study included 101 PD patients who received treatment at our hospital between August 2018 and August 2020. According to the modified Hoehn-Yahr (H-Y) classification, the patients were divided into the early-stage (grade I and II) group (N=21), the mid-stage (grade III) group (N=28), and the late-stage (grade IV) groups (N=20). Detailed information including general data and clinical data was collected. RESULTS: Multivariate logistic regression analysis showed that lower total cholesterol, triglyceride, and uric acid levels were protective factors against the occurrence of sleep disorder, and increased Madopar dosage ≥ 600 mg, Self-rating Anxiety Scale (SAS), and Self-rating Depression Scale (SDS) were risk factors for the occurrence of sleep disorder. The levels of total cholesterol, triglyceride, and uric acid, total sleep time, sleep efficiency, REM sleep latency score, minimum oxygen saturation, and Madopar dosage ≥ 600 mg in the late-stage group were lower than those in the mid-stage group. Meanwhile, homocysteine levels, Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, SAS, SDS score, sleep latency score, hypopnea index, the number of times of waking up, and the number of episodes of hypopnea and apnea were higher than those in the mid-stage group. CONCLUSIONS: Decreased levels of total cholesterol, triglyceride, and uric acid were associated with the occurrence of PD. Lower Madopar doses and reducing anxiety and depression might control the occurrence and development of sleep disorders in PD patients.
OBJECTIVE: This study aimed to explore the spectrum characteristics of Parkinson's disease (PD) patients with sleep disorders. METHODS: This retrospective study included 101 PD patients who received treatment at our hospital between August 2018 and August 2020. According to the modified Hoehn-Yahr (H-Y) classification, the patients were divided into the early-stage (grade I and II) group (N=21), the mid-stage (grade III) group (N=28), and the late-stage (grade IV) groups (N=20). Detailed information including general data and clinical data was collected. RESULTS: Multivariate logistic regression analysis showed that lower total cholesterol, triglyceride, and uric acid levels were protective factors against the occurrence of sleep disorder, and increased Madopar dosage ≥ 600 mg, Self-rating Anxiety Scale (SAS), and Self-rating Depression Scale (SDS) were risk factors for the occurrence of sleep disorder. The levels of total cholesterol, triglyceride, and uric acid, total sleep time, sleep efficiency, REM sleep latency score, minimum oxygen saturation, and Madopar dosage ≥ 600 mg in the late-stage group were lower than those in the mid-stage group. Meanwhile, homocysteine levels, Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, SAS, SDS score, sleep latency score, hypopnea index, the number of times of waking up, and the number of episodes of hypopnea and apnea were higher than those in the mid-stage group. CONCLUSIONS: Decreased levels of total cholesterol, triglyceride, and uric acid were associated with the occurrence of PD. Lower Madopar doses and reducing anxiety and depression might control the occurrence and development of sleep disorders in PD patients.
Authors: Hind A Beydoun; Jiu-Chiuan Chen; Nazmus Saquib; Michelle J Naughton; May A Beydoun; Aladdin H Shadyab; Lauren Hale; Alan B Zonderman Journal: J Affect Disord Date: 2022-06-22 Impact factor: 6.533